ImMI-Tx

Understanding how the gut microbiome and tumour environment influence cancer immunotherapies

The ImMI-Tx project aims to better understand the role of the gut microbiome – the community of microorganisms living naturally in the digestive tract – and the tumour’s surrounding environment in shaping patient response to cancer immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC). Immunotherapy works by helping the body’s immune system recognise and attack cancer cells, but its effectiveness can vary from one person to another, and some patients experience side effects related to the immune system. By combining clinical information with advanced molecular analyses of biological samples, the project aims to identify biomarkers that can predict treatment effectiveness, survival, and the risk of side effects. These discoveries will support the development of more personalised immunotherapy strategies and help clinicians select the most appropriate treatment for each patient.

About the study

Recruiting

Patients 18+ years

Oncological diseases

Locations

Centre Hospitalier de Luxembourg – CHL Centre 4 rue Barblé
L-1210 Luxembourg

Hôpitaux Robert Schuman (HRS) – Cabinet de Pneumologie 56, rue d’Anvers
L-1130 Luxembourg

Contact

For further information or to take part in ImMI-Tx, please contact your oncologist directly.

Who can participate?

Eligible participants

Are 18 years of age or older.
Have been diagnosed with advanced non-small cell lung cancer (NSCLC) that cannot be treated with surgery or radiotherapy.
Are about to start your first immunotherapy treatment, either alone or in combination with chemotherapy.
Have measurable disease that can be monitored during the study.
Have not previously received treatment for your advanced lung cancer (or completed any previous adjuvant treatment at least 6 months before joining the study).
Have not received antibiotics within the past 8 weeks.
Are willing and able to attend study visits, provide biological samples, and complete the study procedures.
Are able to understand the study information and provide written informed consent.

Exclusion criteria

Have another active cancer that requires treatment (with the exception of certain fully treated skin cancers or carcinoma in situ).
Have a type of lung cancer with a genetic alteration for which an approved targeted therapy is available.
Have a medical or psychiatric condition that could make participation unsafe or interfere with the study procedures.
Are pregnant, planning to become pregnant, or breastfeeding.
Require high-dose steroid treatment or other medications that significantly suppress the immune system.

Not sure about eligibility?

The study team will review each case individually to determine eligibility. If you are unsure whether you are eligible, do not hesitate to contact us.

What will participants do?

01.

Attend a routine visit

This will take place before starting immunotherapy and will include providing your written informed consent and completing the study assessments.

02.

Provide biological samples

Three blood samples and one stool sample will be collected at the start of the study and then approximately every 12 weeks until your disease progresses.

02.